Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001334998 | SCV001528022 | uncertain significance | Leukocyte adhesion deficiency type II | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001334998 | SCV002311583 | uncertain significance | Leukocyte adhesion deficiency type II | 2021-01-10 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with SLC35C1-related conditions. This variant is present in population databases (rs757642463, ExAC 0.02%). This sequence change replaces glycine with serine at codon 333 of the SLC35C1 protein (p.Gly333Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. |